CompletedNCT00530335
Atomoxetine for ADHD in adults in Japan
About this title
Read the official source — NCT00530335Medication studyAges 18+Japan
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Aichi and 11 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 45
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Japan
- Age range
- Over 18 Years
- Official registry ID
- NCT00530335
- Official title
Show the full official title
An Open-Label Pilot Study for Atomoxetine in Adult Subjects With Attention Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Aichi · Chiba · Fukushima
9 more locations
- Hokkaido
- Hyōgo
- Ishikawa
- Kanagawa
- Kumamoto
- Kyoto
- Nara
- Saitama
- Tokyo
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
This study was for people with ADHD. Listed age limits: from 18 years. Other eligibility criteria applied.
